Amol Akhade: Late-Breaking Abstracts, Major MDT Sessions, and Colorectal Cancer Trials to Watch at ASCO GI 2026

Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:

“ASCO GI 2026 highlights how GI oncology is evolving—not just through new drugs, but through better patient selection, sequencing, and multidisciplinary decision-making.

 Late-Breaking Abstracts to watch out

1. ILUSTRO (Kohei Shitara et al.): zolbetuximab + mFOLFOX6 + nivolumab in CLDN18.2+ gastric/GEJ adenocarcinoma•
2.  HERIZON-GEA-01 (Elena Elimova et al.): zanidatamab + chemotherapy ± tislelizumab in HER2-positive GEA
3.  LyRICX (Denice Kamp et al.): liposomal irinotecan + platinum ± nivolumab in first-line esophagogastric adenocarcinoma

 Major MDT Sessions

1. Liver Power Hour hepatobiliary tumor board (Nina Sanford, Riad Salem)
2. Managing liver tumors with hepatic dysfunction—control vs toxicity
3. Organ preservation in GEJ/gastric cancer
4. MDT approaches in borderline and locally advanced pancreatic cancer
5. T2 rectal cancer management innovations

 Colorectal Cancer Trials to Look forward.

1. BREAKWATER (Scott Kopetz et al.): encorafenib + cetuximab + FOLFIRI in BRAF V600E mCRC
2. COMMIT (Caio Rocha Lima et al.): IO alone vs IO-chemo in dMMR/MSI-H mCRC

The recurring message: progress will depend less on enthusiasm and more on judgment—who, when, and how.”

More posts featuring Amol Akhade.